Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Peritoneal Cancer Clinical Trials

A listing of Peritoneal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (17) clinical trials

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

7 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab. This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and ...


A clinical trial seeking patients for a research study of AZD1775

Study Drug Administration: A study cycle is 28 days. If you are found to be eligible to take part in this study, you will begin taking AZD1775 on the day of your laparoscopy. You will first take AZD1775 tablets 2 times each day on Days 1-3. Depending on when your ...

Phase N/A

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Study Groups: This study has 2 parts: a safety lead-in and Phase 2. If you are found to be eligible to take part in this study, you will be assigned to either the Safety Lead-in or the Phase 2 portion, depending on when you join the study. Up to 12 ...


A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Epithelial gynecologic malignancies are tumors of mllerian origin, which include ovarian, endometrial, fallopian tube, and primary peritoneal cancers, and account for >70,000 new diagnoses and >22,000 deaths per year in the United States alone. Treatment typically consists of a thorough cytoreductive and staging surgery in combination with platinum/taxane chemotherapy. Newer ...

Phase N/A

AZD1775 Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer

This is an open-label, four-arm lead-in safety and efficacy study in which AZD1775 will be combined in four separate treatment arms as follows: AZD1775 plus gemcitabine (Arm A); AZD1775 plus weekly paclitaxel (Arm B); AZD1775 plus carboplatin (Arm C); and AZD1775 plus PLD (Arm D). A subset of patients will ...


Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVE: I. Determine the safety and feasibility of NY-ESO-1 protein with MIS416 in combination with mammalian target of rapamycin (mTOR) inhibitor sirolimus. SECONDARY OBJECTIVES: I. To determine the effectiveness of these combinatorial therapies by assessing NY-ESO-1 specific cellular and humoral immunity: peripheral blood NY-ESO-1 specific cluster of differentiation (CD)8+ ...


Pilot Trial of BMN 673 an Oral PARP Inhibitor in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Background The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of DNA damage repair mechanisms. Talazoparib (BMN 673) is a PARP inhibitor with greater in vitro activity than any other PARP inhibitor currently in development. Talazoparib (BMN 673) has been shown ...


A clinical trial to evaluate treatments using Paclitaxel, Carboplatin, Atezolizumab Placebo, Atezolizumab, Bevacizumab for patients with Ovarian Cancer, Peritoneal Neoplasm, Fallopian Tube Cancer

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary ...


A clinical trial sponsored by National Cancer Institute (NCI) for a research study for the treatment of Recurrent Ovarian Carcinoma, Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma

PRIMARY OBJECTIVES: I. Assess and compare progression free survival (PFS) between gemcitabine (gemcitabine hydrochloride)/VX-970 and gemcitabine alone arms. SECONDARY OBJECTIVES: I. Determine and compare overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) between gemcitabine/VX-970 and gemcitabine alone arms. II. Determine and compare the safety profile of ...